$0.70
3.05% today
Nasdaq, Apr 03, 06:47 pm CET
ISIN
US81750R1023
Symbol
MCRB
Sector
Industry

Seres Therapeutics Inc Stock price

$0.68
-0.07 9.44% 1M
-0.22 24.86% 6M
-0.15 18.41% YTD
-0.08 11.12% 1Y
-6.94 91.10% 3Y
-2.48 78.54% 5Y
-50.72 98.68% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.00 0.27%
ISIN
US81750R1023
Symbol
MCRB
Sector
Industry

Key metrics

Market capitalization $118.22m
Enterprise Value $179.07m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 8.51
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-129.11m
Free Cash Flow (TTM) Free Cash Flow $-148.99m
Cash position $30.79m
EPS (TTM) EPS $-0.96
P/E forward negative
P/S forward 3.57
EV/Sales forward 5.41
Short interest 15.63%
Show more

Is Seres Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Seres Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Seres Therapeutics Inc forecast:

4x Buy
57%
1x Hold
14%
2x Sell
29%

Analyst Opinions

7 Analysts have issued a Seres Therapeutics Inc forecast:

Buy
57%
Hold
14%
Sell
29%

Financial data from Seres Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 7.48 7.48
50% 50%
-
-7.48 -7.48
107% 107%
-
- Selling and Administrative Expenses 45 45
21% 21%
-
- Research and Development Expense 69 69
53% 53%
-
-122 -122
32% 32%
-
- Depreciation and Amortization 7.48 7.48
50% 50%
-
EBIT (Operating Income) EBIT -129 -129
20% 20%
-
Net Profit -147 -147
29% 29%
-

In millions USD.

Don't miss a Thing! We will send you all news about Seres Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Seres Therapeutics Inc Stock News

Neutral
Seeking Alpha
21 days ago
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Carlo Tanzi - Kendall Investor Relations Eric Shaff - President and Chief Executive Officer Lisa von Moltke - Executive Vice President and Chief Medical Officer Matthew Henn - Executive Vice President and Chief Scientific Officer Terri Young - Executive Vice President, Chief C...
Neutral
GlobeNewsWire
21 days ago
Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) at day 30 post-HSCT; Company expects to submit draft study protocol to FDA in Q2 2025
Neutral
GlobeNewsWire
about one month ago
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) --  Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on March 13, 2025 at 8:30 a.m.
More Seres Therapeutics Inc News

Company Profile

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Head office United States
CEO Eric Shaff
Employees 103
Founded 2010
Website www.serestherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today